• Alzheimer's Disease as a Neurovascular Inflammatory Disorder

    Alzheimer's Disease as a Neurovascular Inflammatory Disorder

    Keynote Speaker: Costantino Iadecola (Weill Cornell Medicine)Presented by the Biochemical Pharmacology Discussion Group
    Reported by Alla Katsnelson | Posted April 3, 2017


    For the past several decades Alzheimer's disease has been framed as a neurological disorder, and therapeutic efforts—all, to date, unsuccessful—have largely focused on interfering with the accumulation of amyloid beta protein deposits. However, the appreciation and understanding of how vascular dysfunction contributes to disease pathology is growing, and inflammatory contributors are also under intense investigation. On December 6, the Academy brought together researchers currently investigating a variety of vascular and inflammatory mechanisms that could contribute to the disease to share insights and promising therapeutic targets. Topics included ongoing research on the roles of different cell types in the vasculature, defining the intersection between vascular and inflammatory factors, and proposed mechanisms through which these pathways could contribute to Alzheimer's disease pathology.

    Use the tabs above to find a meeting report and multimedia from this event.

    Presentations available from:
    Katerina Akassoglou, PhD (University of California, San Francisco)
    Robert Dempsey, MD (University of Wisconsin)
    Zorina Galis, PhD (National Institutes of Health / National Heart, Lung, and Blood Institute)
    Paula Grammas, PhD (University of Rhode Island)
    Jaime Grutzendler, MD (Yale University)
    Costantino Iadecola, MD (Weill Cornell Medicine)
    Jeffrey Iliff, PhD (Oregon Health & Science University)
    C. Elizabeth Shaaban, MPH (University of Pittsburgh)
    Heather Snyder, PhD (Alzheimer's Association)
    Berislav Zlokovic, MD PhD (Keck School of Medicine of USC)

    The Biochemical Pharmacology Discussion Group is proudly supported by:

    • Boehringer Ingelheim
    • Regeneron

    American Chemical Society

    Premiere Supporter

    • Pfizer

    Grant Support

    Funding for this conference was made possible, in part, by R13NS098718 from the National Institute of Neurological Disorders and Stroke. Co-funding has been provided by the National Heart, Lung, and Blood Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official views of the National Institutes of Health; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    How to cite this eBriefing

    The New York Academy of Sciences. Alzheimer's Disease as a Neurovascular Inflammatory Disorder. Academy eBriefings. 2016. Available at: